CRCL adjuvant effects are T cell dependent.
(A) 12B1-D1 cells were treated with 40 nM AP20187 for 6 hours and then washed. Then 20 μg/mouse liver–derived CRCL or 10 μg/mouse LPS was added to the cells and the mixture was subcutaneously injected into the right groin of SCID mice. Control mice were immunized with an equal number of AP20187-treated 12B1-D1 cells alone. (P = NS; n = 8 mice per group; representative data from o1 of 2 experiments are shown.) (B) On days −14 and −7, BALB/c mice were subcutaneously injected with 2 × 106 Mit-C–treated 12B1-D1 cells that were mixed with 20 μg/mouse liver–derived CRCL in the right groin. On days −3, −1, +1, and +7, mice were intraperitoneally injected with 200 μg/mouse anti-CD4 or anti-CD8 mAb (or both), or the same volume of saline. Control mice were immunized with equal number of Mit-C–treated 12B1-D1 cells or saline. On day 0, mice were injected with 2 × 104 (LD100) 12B1-D1 cells subcutaneously. (Saline versus 12B1-D1/Mit-C, or double depletionP = NS; saline versus CRCL P < 005 from day 15 onward; saline versus CD4 or CD8 depletion P < .05 from day 17 onward; CD4 depletion versus CD8 depletionP = NS; n = 8-24 mice per group. Representative data from 1 of 2 experiments are shown.)
